Evidence map›Paper›PMID 22102814›Full record

ArticlePLoS pathogens2011

CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection.

Kristen Haberthur, Flora Engelmann, Byng Park, Alex Barron, Alfred Legasse, Jesse Dewane, Miranda Fischer, Amelia Kerns, Monica Brown, Ilhem Messaoudi

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 95 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Varicella zoster virus infection.Nature reviews. Disease primers · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Animal models of human herpesvirus infection.Animal models and experimental medicine · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kristen HaberthurDepartment of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, United States of America.
Flora Engelmann
Byng Park
Alex Barron
Alfred Legasse
Jesse Dewane
Miranda Fischer
Amelia Kerns
Monica Brown
Ilhem Messaoudi
Oregon Health & Science University · USOregon National Primate Research Center · US

Funding

YR 50 PROJ- ROBERTS PRIMATE ISLETP51RR000163 · NCRR · OREGON REGIONAL PRIMATE RESEARCH CENTER · PI OJEDA, SERGIO R · 1985 to 2011
$140.8M
Impact of immune senescence on herpes zoster in a nonhuman primate modelR01AG037042 · NIA · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI MESSAOUDI, ILHEM · 2010 to 2014
$2.3M
Inflammation and T Lymphocyte ImmunoregulationT32AI078903 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI HILL, ANN B · 2009 to 2013
$1.5M
NCRR NIH HHS P51 RR000163NCRR NIH HHS P51 RR00163-51NIAID NIH HHS T32 AI078903NIA NIH HHS R01 AG037042
6 · The paper itself

Abstract

Primary infection with varicella zoster virus (VZV) results in varicella (more commonly known as chickenpox) after which VZV establishes latency in sensory ganglia. VZV can reactivate to cause herpes zoster (shingles), a debilitating disease that affects one million individuals in the US alone annually. Current vaccines against varicella (Varivax) and herpes zoster (Zostavax) are not 100% efficacious. Specifically, studies have shown that 1 dose of varivax can lead to breakthrough varicella, albeit rarely, in children and a 2-dose regimen is now recommended. Similarly, although Zostavax results in a 50% reduction in HZ cases, a significant number of recipients remain at risk. To design more efficacious vaccines, we need a better understanding of the immune response to VZV. Clinical observations suggest that T cell immunity plays a more critical role in the protection against VZV primary infection and reactivation. However, no studies to date have directly tested this hypothesis due to the scarcity of animal models that recapitulate the immune response to VZV. We have recently shown that SVV infection of rhesus macaques models the hallmarks of primary VZV infection in children. In this study, we used this model to experimentally determine the role of CD4, CD8 and B cell responses in the resolution of primary SVV infection in unvaccinated animals. Data presented in this manuscript show that while CD20 depletion leads to a significant delay and decrease in the antibody response to SVV, loss of B cells does not alter the severity of varicella or the kinetics/magnitude of the T cell response. Loss of CD8 T cells resulted in slightly higher viral loads and prolonged viremia. In contrast, CD4 depletion led to higher viral loads, prolonged viremia and disseminated varicella. CD4 depleted animals also had delayed and reduced antibody and CD8 T cell responses. These results are similar to clinical observations that children with agammaglobulinemia have uncomplicated varicella whereas children with T cell deficiencies are at increased risk of progressive varicella with significant complications. Moreover, our studies indicate that CD4 T cell responses to SVV play a more critical role than antibody or CD8 T cell responses in the control of primary SVV infection and suggest that one potential mechanism for enhancing the efficacy of VZV vaccines is by eliciting robust CD4 T cell responses.

Indexed as

Disease Models, AnimalMacaca mulattaAnimalsAntigens, CD20B-LymphocytesCD4 AntigensCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesChickenpoxChickenpox VaccineHerpesviridae InfectionsHerpesvirus 3, HumanVaricellovirusViral LoadVirus ReplicationAntigens, CD20CD4 AntigensChickenpox Vaccine

Identifiers

PMID22102814
PMCPMC3213099
OpenAlexW2043130534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.